生物技术公司Cha Bio Tech,3000亿韩元有偿增资由Kakao单独参与……生物技术与平台联盟的信号弹?

TechubNews

科斯达克上市公司Cha Bio Tec于11月19日决定实施规模约300亿韩元的第三方配售有偿增资。此次融资被解读为旨在获取其他法人证券等经营战略及财务稳定化。

本次有偿增资中,Cha Bio Tec拟以每股1.2499万韩元的价格发行240.0192万股普通股。以股票发行价款为基准计算,募集资金总额规模约达300亿韩元。新股将配售给外部投资者Kakao株式会社,实际以独家投资形式进行。

Cha Bio Tec是主营生物医药品开发及干细胞治疗剂研究的科斯达克代表性生物企业之一。近期正加速拓展新研发管线及相关企业投资等外延扩张,此次有偿增资也被视为该经营战略的一环。

值得注意的是Kakao参与了此次有偿增资。该公司近期除平台业务外,持续被推测可能进军数字医疗、生物产业等新增长领域。通过此次投资,其与Cha Bio Tec建立战略联盟的可能性也无法排除,正引发业界高度关注。

根据Cha Bio Tec后续对募集资金的实际运用方向,其中长期企业价值可能产生变化。若与Kakao的合作关系趋于明朗,则有望构建生物产业新型合作伙伴关系范式。

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Opmerking
0/400
Geen opmerkingen